生物製造市场－全球产业规模、份额、趋势、机会和预测，按工作流程、按应用、按最终用户、按地区和竞争进行细分，2020 年至 2030 年

2024 年全球生物製造市场价值为 190.8 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 7.72%。生物製造市场是生物技术和製药行业的一个重要部分，专注于生物衍生产品的大规模生产。这些产品包括单株抗体、治疗性蛋白质、细胞和基因疗法、疫苗等生物製药，以及无法透过传统化学合成生产的复杂生物製品。生物製造涉及一系列复杂的过程，包括细胞培养、发酵、纯化和品质控制，通常需要高度受控的环境和先进的生物反应器系统。这个市场在确保全球患者能够获得拯救生命和改善生活的疗法方面发挥着至关重要的作用。在个人化医疗需求不断增长、慢性病患病率上升以及基因工程快速发展的推动下，生物製造业正在经历大幅增长。

例如，根据世界卫生组织统计，糖尿病患者数量从 1990 年的 2 亿增加到 2022 年的 8.3 亿。中低收入国家的糖尿病患者数量成长速度明显快于高收入国家，凸显了全球健康挑战日益严峻，发展中国家需要有针对性的预防和管理策略。一次性技术、自动化和连续生物加工等创新正在改变生产能力、提高效率并降低成本。生物药物研发管线的不断扩大和生物相似药的出现正在为市场创造新的机会。监管机构也在进行调整，以支持加快审批和提高生产弹性。随着科学研究的不断进步，生物製造市场将在应对全球医疗保健挑战方面发挥越来越重要的作用，从而加快下一代疗法的开发和分销。

关键市场驱动因素

采用先进技术与新创新

主要市场挑战

巨额资本支出

主要市场趋势

连续生物製造的出现

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球生物製造市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依工作流程（连续上游生物製造、一次性上游生物製造、下游生物製造）
  • 依应用（单株抗体、荷尔蒙、疫苗、重组蛋白、其他）
  • 按最终用户（生物製药公司、研究机构、CMO/CDMO）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美生物製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲生物製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太生物製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲生物製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲生物製造市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Illumina Inc.
• Thermo Fischer Scientific Inc.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• BGI Genomics Co. Ltd.
• PerkinElmer Inc.
• QIAGEN NV
• Eurofins Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Takara Bio Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Bio-Manufacturing Market has valued at USD 19.08 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.72% through 2030. The biomanufacturing market is a vital segment within the biotechnology and pharmaceutical industry, focusing on the large-scale production of biologically derived products. These include biopharmaceuticals such as monoclonal antibodies, therapeutic proteins, cell and gene therapies, vaccines, and other complex biological products that cannot be produced through traditional chemical synthesis. Biomanufacturing involves a range of sophisticated processes, including cell culture, fermentation, purification, and quality control, often requiring highly controlled environments and advanced bioreactor systems. This market plays a crucial role in ensuring the availability of life-saving and life-enhancing therapies for patients across the globe. Driven by increasing demand for personalized medicine, rising prevalence of chronic diseases, and rapid advances in genetic engineering, the biomanufacturing sector is experiencing substantial growth.

For instance, according to WHO, the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022. The rise has been significantly faster in low- and middle-income countries compared to high-income nations, highlighting a growing global health challenge and the need for targeted prevention and management strategies in developing regions. Innovations such as single-use technologies, automation, and continuous bioprocessing are transforming production capabilities, enhancing efficiency, and reducing costs. The expanding pipeline of biologic drugs and the emergence of biosimilars are creating new opportunities within the market. Regulatory agencies are also adapting to support accelerated approvals and manufacturing flexibility. As scientific research continues to advance, the biomanufacturing market is poised to become increasingly essential in addressing global healthcare challenges, enabling faster development and distribution of next-generation therapies.

Key Market Drivers

Adoption of Advanced Technology and New Innovation

The rise in the geriatric population and the prevalence of chronic respiratory disorders are anticipated to drive the demand for ventilators. Increasing awareness of lung cancer symptoms and a growing number of patients in medical facilities contribute to the significant market growth of ventilators. For instance, in November 2023, the FDA approved Ixchiq, the first vaccine for chikungunya, for adults aged 18 and older. In December 2023, the FDA approved Casgevy and Lyfgenia-the first cell-based gene therapies-for treating sickle cell disease in patients aged 12 and older, marking major milestones in infectious disease prevention and genetic disorder treatment. However, it should be noted that the use of mechanical ventilation may pose certain risks, such as increased infection risk and potential damage to the lungs. These considerations should be taken into account when assessing the market growth potential of Bio-Manufacturing. Advanced technologies such as automation, robotics, and process control systems can streamline biomanufacturing processes, reduce human error, and enhance overall production efficiency. This can lead to quicker turnaround times and increased production capacity, meeting the growing demand for biologics. Innovative bioreactor designs, single-use technologies, and flexible manufacturing platforms allow for easier scalability of production. As demand for bio manufactured products grows, the ability to quickly scale up production will become essential. Continuous manufacturing approaches, as opposed to traditional batch processes, can lead to consistent product quality, reduced wastage, and improved resource utilization. These advantages can boost demand for bio manufactured products.

Key Market Challenges

Huge Capital Expenditure

The biomanufacturing process involves intricate and specialized equipment, facilities, and technologies, which can require significant financial investments. Setting up a biomanufacturing facility or upgrading existing infrastructure requires substantial initial capital investment. This includes the construction or renovation of specialized cleanrooms, purchase of bioreactors, purification equipment, and other sophisticated tools necessary for biopharmaceutical production. The substantial capital required for biomanufacturing can divert resources away from other critical areas such as research and development, marketing, and business expansion. This resource allocation challenge can impact a company's overall growth strategy. The high capital expenditure can result in overestimation or underutilization of manufacturing capacity. If demand for the manufactured product is lower than anticipated, the investment may not yield the expected returns.

Key Market Trends

Emergence of Continuous Biomanufacturing

The emergence of continuous biomanufacturing has the potential to significantly boost the growth of the biomanufacturing industry in the future. Continuous biomanufacturing represents a departure from traditional batch processes by enabling the seamless, uninterrupted production of biopharmaceuticals and other biologically derived products. This innovative approach offers several benefits that can positively impact efficiency, flexibility, cost-effectiveness, and overall market expansion. Continuous biomanufacturing allows for continuous monitoring and adjustment of process parameters in real-time. This leads to improved process control, reduced variability, and enhanced product consistency, resulting in higher process efficiency and reduced production times. Continuous biomanufacturing systems are generally more compact and require less physical space than traditional batch systems. This reduction in facility footprint can lead to cost savings and greater flexibility in facility design and location. Continuous biomanufacturing can enable higher production capacities by running processes continuously, thereby increasing output without the need for significant facility expansion. This increased capacity can meet the growing demand for biopharmaceuticals and other biologically derived products.

Key Market Players

Illumina Inc.

Thermo Fischer Scientific Inc.

Oxford Nanopore Technologies plc

Agilent Technologies, Inc.

BGI Genomics Co. Ltd.

PerkinElmer Inc.

QIAGEN NV

Eurofins Scientific Inc.

F. Hoffmann-La Roche Ltd

Takara Bio Inc.

Report Scope:

In this report, the Global Bio-Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bio-Manufacturing Market, By Workflow:

• Continuous Upstream Biomanufacturing
• Single-Use Upstream Biomanufacturing
• Downstream Biomanufacturing

Bio-Manufacturing Market, By Application:

• Monoclonal Antibodies
• Hormones
• Vaccines
• Recombinant Proteins
• Others

Bio-Manufacturing Market, By End User:

• Biopharmaceutical Companies
• Research Institutions
• CMOs/CDMOs

Bio-Manufacturing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bio-Manufacturing Market.

Available Customizations:

Global Bio-Manufacturing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bio-Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing)
  • 5.2.2. By Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others)
  • 5.2.3. By End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Bio-Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bio-Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Bio-Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Bio-Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe Bio-Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bio-Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. United Kingdom Bio-Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. Italy Bio-Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. France Bio-Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Bio-Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Bio-Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bio-Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Bio-Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Bio-Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Bio-Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Bio-Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. South America Bio-Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bio-Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Bio-Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Bio-Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Bio-Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bio-Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Bio-Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Bio-Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Illumina Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Thermo Fischer Scientific Inc.
• 14.3. Oxford Nanopore Technologies plc
• 14.4. Agilent Technologies, Inc.
• 14.5. BGI Genomics Co. Ltd.
• 14.6. PerkinElmer Inc.
• 14.7. QIAGEN NV
• 14.8. Eurofins Scientific Inc.
• 14.9. F. Hoffmann-La Roche Ltd
• 14.10. Takara Bio Inc.

15. Strategic Recommendations

16. About Us & Disclaimer